Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€30.00

€30.00

-
-
-
-
 
03.04.24 / Tradegate WKN: A116DD / Name: CymaBay / Stock / Biotechnology & Medical Research / Small Cap / We currently do not receive price updates for this security
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Cymabay Therapeutics Inc is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for CymaBay

sharewise wants to provide you with the best news and tools for CymaBay, so we directly link to the best financial data sources.

News

3 Dividend Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/768447/excited-investor-looks-at-financial-charts-on-computer.jpg
3 Dividend Stocks to Buy Hand Over Fist in March

Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend stocks can enjoy. Three Motley Fool contributors believe they've identified

Analysts see over 50% gains in these 2 mid-cap biotech stocks: https://www.marketbeat.com/logos/articles/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg
Analysts see over 50% gains in these 2 mid-cap biotech stocks

2024 is shaping up to be a pivotal year for the biotechnology industry.

In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way